公开(公告)号：EP3192875A1

公开(公告)日：2017-07-19

申请号：EP15840177.8

申请日：2015-09-09

申请人： Daiichi Sankyo Co., Ltd.

发明人： KASUYA, Yuji ,  NAKAGAMI, Yasuhiro ,  HATANO, Emiko ,  INOUE, Tatsuya ,  YOSHIDA, Kazuhiro ,  KOMORIYA, Satoshi ,  MURAKAMI, Yoko ,  IWASAKI, Masaru ,  SAKAMOTO, Atsunobu ,  MASUDA, Kayoko ,  MINAMI, Masako ,  IIZUKA, Mayumi ,  ONO, Yasunori ,  OHNUKI, Takashi

IPC分类号： C12P33/06 ,  A61K9/52 ,  A61K31/277 ,  A61K31/336 ,  A61K47/34 ,  A61P1/16

摘要： The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body

摘要翻译： 本发明涉及具有激活Keap1 / Nrf2 / ARE信号传导途径的能力并且具有优异的抗炎作用和细胞保护作用的萜类衍生物，以及对于治疗和预防后部结构有效的缓释药物组合物 包含萜类衍生物作为活性成分的氧化应激引起的眼病。 本发明提供含有本发明的萜类衍生物作为有效成分的用于治疗或预防后眼病的局部给药型缓释药物组合物，其中所述缓释药物组合物保持其药理作用 通过在生理条件下持续释放萜类衍生物1周或更长时间，并且具有可给予玻璃体的基质材料和玻璃体可施用的形式